CHICAGO – Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA...
CHICAGO – PD-1 blockade with dostarlimab (Jemperli) induced complete tumor clearance and resolved the need for surgery in patients...
CHICAGO – Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced...
CHICAGO – Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in patients...
The AACR Trailblazer Cancer Research Grant Program will award $15 million over three years CHICAGO – The American Association...
CHICAGO – The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented...
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of William N. Hait, MD, PhD,...
CHICAGO – The American Association for Cancer Research (AACR) will honor leaders from government and the advocacy community with...
PHILADELPHIA – A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy...
Awardees to be recognized at the AACR Annual Meeting 2025 in Chicago CHICAGO – The American Association for Cancer...